Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation

8 Feb 2023

Abstract excerpt

Immunotherapy, especially with immune checkpoint inhibitors (ICIs), has shown advantages in cancer treatment and is a new hope for patients who have failed multiline therapy. However, in colorectal cancer (CRC), the benefit is limited to a small subset of patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic CRC (mCRC). In addition, 45% to 60% of dMMR/MSI-H mCRC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Colorectal Cancer Treatments and Studies
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36752642
DOI: 10.1002/ijc.34464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translationPMID 36752642Read ↗

Immunotherapy for the treatment of colorectal cancerSemantic proximity Read ↗

Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerSemantic proximity Read ↗

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanismsSemantic proximity Read ↗

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair DeficiencySemantic proximity Read ↗

Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging TherapiesSemantic proximity Read ↗

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite InstabilitySemantic proximity Read ↗

Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?Semantic proximity Read ↗

Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.Semantic proximity Read ↗

Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.Semantic proximity Read ↗

Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review)Semantic proximity Read ↗

Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.